Document:

Exhibit 10.12
      

      

      
        FORWARD PURCHASE AGREEMENT

        

        

        This Forward Purchase Agreement (this “Agreement”) is entered into as of July 11, 2019, between SC Health Corporation, a Cayman Islands
          exempted company (the “Company”) and SC Health Group Limited, a Cayman Islands exempted company (the “Purchaser”).

        

        

        Recitals

        

        

        WHEREAS, the Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or
          similar business combination with one or more businesses (a “Business Combination”);

        

        

        WHEREAS, the Company has confidentially submitted to the U.S. Securities and Exchange Commission (the “SEC”) a draft registration statement on
          Form S-1 (the “Registration Statement”) for its initial public offering (“IPO”) of 15,000,000 units (or 17,250,000 units in the aggregate if the underwriters’ over-allotment is exercised in full) (the “Public Units”) at a
          price of $10.00 per Public Unit, each comprised of one Class A ordinary share of the Company, par value $0.0001 per share (the “Class A Share(s)”), and one-half of one redeemable warrant, where each whole redeemable warrant is exercisable
          to purchase one Class A Share at an exercise price of $11.50 per share (the “Warrant(s)”);

        

        

        WHEREAS, following the closing of the IPO (the “IPO Closing”), the Company will seek to identify and consummate a Business Combination;

        

        

        WHEREAS, the parties wish to enter into this Agreement, pursuant to which (i) immediately prior to the closing of the Company’s initial Business
          Combination (the “Business Combination Closing”), the Company shall issue and sell, and the Purchaser shall purchase, on a private placement basis, 5,000,000 Class A Shares (the “Forward Purchase Shares”) and 1,250,000 Warrants (the
          “Forward Purchase Warrant(s)” and together with the Forward Purchase Shares, the “Forward Purchase Securities”);

        

        

        NOW, THEREFORE, in consideration of the premises, representations, warranties and the mutual covenants contained in this Agreement, and for other
          good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

        

        

        Agreement

        

        

        1.          Sale
              and Purchase.

        

        

        (a)          Forward Purchase Securities.

        

        

        (i)          The Company shall issue and sell to the Purchaser, and
            the Purchaser shall purchase from the Company, the number of Forward Purchase Shares set forth on the signature page to this Agreement next to the line item “Number of Forward Purchase Shares,” plus the number of Forward Purchase
            Warrants set forth on the signature page to this Agreement next to the line item “Number of Forward Purchase Warrants,” for an aggregate purchase price of $10.00 multiplied by the number of Forward Purchase Shares issued and sold
            hereunder (the “FPS Purchase Price”).  No fractional Forward Purchase Warrants will be issued.

        
          
            

        

        
        (ii)         Each Forward Purchase Warrant will have the same
            terms as each Warrant sold as part of the Public Units in the IPO (“Public Warrants”) and will be subject to the terms and conditions of the Warrant Agreement to be entered into between the Company and American Stock Transfer & Trust
            Company, LLC, as Warrant Agent, in connection with the IPO (the “Warrant Agreement”).  Each Forward Purchase Warrant will entitle the holder thereof to purchase one Class A Share at a price of $11.50 per share, subject to adjustment as
            described in the Warrant Agreement, and only whole Forward Purchase Warrants will be exercisable.  The Forward Purchase Warrants will become exercisable on the later of thirty (30) days after the Business Combination Closing and twelve (12)
            months from the closing of the IPO, and will expire at 5:00 p.m., New York City time, five (5) years after the Business Combination Closing or earlier upon redemption or the liquidation of the Company, as described in the Warrant Agreement.

        

        

        (iii)        The Company shall require the Purchaser to purchase
            the Forward Purchase Shares and the Forward Purchase Warrants pursuant to Section 1(a)(i) hereof by delivering notice to the Purchaser, at least ten (10) Business Days before the funding of the FPS Purchase Price to an account specified by the
            Company, specifying the number of Forward Purchase Shares and Forward Purchase Warrants the Purchaser is required to purchase, the anticipated date of the Business Combination Closing, the aggregate FPS Purchase Price and instructions for
            wiring the FPS Purchase Price to an account designated by the Company.  At least two (2) Business Days before the anticipated date of the Business Combination Closing specified in such notice, the Purchaser shall deliver the FPS Purchase Price
            in cash via wire transfer to the account specified in such notice, to be held in escrow pending the Business Combination Closing.  If the Business Combination Closing does not occur within thirty (30) days after the Purchaser delivers the FPS
            Purchase Price to such account, the Company shall return to the Purchaser the FPS Purchase Price, provided that the return of the FPS Purchase Price placed in escrow shall not terminate this Agreement or otherwise relieve either party
            of any of its obligations hereunder.  For the purposes of this Agreement, “Business Day” means any day, other than a Saturday or a Sunday, that is neither a legal holiday nor a day on which banking institutions are generally authorized
            or required by law or regulation to close in the City of New York, New York or Singapore.

        

        

        (iv)        The closing of the sale of the Forward Purchase
            Securities (the “FPS Closing”) shall be held on the same date and immediately prior to the Business Combination Closing (such date being referred to as the “Closing Date”).  At the FPS Closing, the Company will issue to the
            Purchaser the Forward Purchase Securities, each registered in the name of the Purchaser.

        

        

        (b)          Delivery of Forward Purchase Securities.

        

        

        (i)           The Company shall register the Purchaser as the
            owner of the Forward Purchase Securities in the register of members of the Company and with the Company’s transfer agent by book entry on or promptly after (but in no event more than two (2) Business Days after) the date of the FPS Closing.

        
          2

          
            

        

        (ii)         Each register and book entry for the Forward Purchase
            Securities shall contain a notation, and each certificate (if any) evidencing the Forward Purchase Securities shall be stamped or otherwise imprinted with a legend, in substantially the following form:

        

        

        “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY
          STATE OR OTHER JURISDICTION, AND MAY NOT BE TRANSFERRED IN VIOLATION OF SUCH ACT AND LAWS.”

        

        

        (c)          Legend Removal.  If the Forward Purchase
            Securities are eligible to be sold without restriction under, and without the Company being in compliance with the current public information requirements of, Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”),
            or there is an effective registration statement covering the resale of the Forward Purchase Securities (and the Purchaser provides the Company with a written undertaking to sell its Forward Purchase Securities only in accordance with the plan
            of distribution contained in such registration statement and only if such Purchaser has not been informed that the prospectus in such registration statement is not current or the registration statement is no longer effective), then at the
            Purchaser’s request, the Company will cause the Company’s transfer agent to remove the legend set forth in Section 1(b)(ii).  In connection therewith, if required by the Company’s transfer agent, the Company will promptly cause an opinion of
            counsel to be delivered to and maintained with its transfer agent, together with any other authorizations, certificates and directions required by the transfer agent that authorize and direct the transfer agent to transfer such Forward Purchase
            Securities without any such legend; provided, that, notwithstanding the foregoing, the Company will not be required to deliver any such opinion, authorization, certificate or direction if it reasonably believes that removal of the
            legend could result in or facilitate transfers of Forward Purchase Securities in violation of applicable law.

        

        

        (d)          Registration Rights.  The Purchaser shall have
            registration rights as set forth on Exhibit A (the “Registration Rights”).

        

        

        2.          Representations

              and Warranties of the Purchaser.  The Purchaser represents and warrants to the Company as follows, as of the date hereof:

        

        

        (a)          Organization and Power.  The Purchaser is an
            exempted company duly incorporated and validly existing and in good standing as an exempted company under the laws of the Cayman Islands and has all requisite corporate power and authority to carry on its business as presently conducted and as
            proposed to be conducted.

        

        

        (b)        Authorization.  The Purchaser has full power and
            authority to enter into this Agreement.  This Agreement, when executed and delivered by the Purchaser, will constitute the valid and legally binding obligation of the Purchaser, enforceable in accordance with its terms, except (a) as limited by
            applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors’ rights generally, (b) as limited by laws relating to the availability of specific
            performance, injunctive relief or other equitable remedies, or (c) to the extent the indemnification provisions contained in the Registration Rights may be limited by applicable federal or state securities laws.

        
          3

          
            

        

        (c)         Governmental Consents and Filings.  No consent,
            approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Purchaser in connection with the consummation of the
            transactions contemplated by this Agreement.

        

        

        (d)          Compliance with Other Instruments.  The
            execution, delivery and performance by the Purchaser of this Agreement and the consummation by the Purchaser of the transactions contemplated by this Agreement will not result in any violation or default (i) of any provisions of its
            organizational documents, if applicable, (ii) of any instrument, judgment, order, writ or decree to which it is a party or by which it is bound, (iii) under any note, indenture or mortgage to which it is a party or by which it is bound, (iv)
            under any lease, agreement, contract or purchase order to which it is a party or by which it is bound or (v) of any provision of federal or state statute, rule or regulation applicable to the Purchaser, in each case (other than clause (i)),
            which would have a material adverse effect on the Purchaser or its ability to consummate the transactions contemplated by this Agreement.

        

        

        (e)         Purchase Entirely for Own Account.  This
            Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Forward Purchase Securities to be acquired by the
            Purchaser will be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting
            any participation in, or otherwise distributing the same in violation of law.  By executing this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any
            Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the Forward Purchase Securities.  If the Purchaser was formed for the specific purpose of acquiring the Forward Purchase Securities,
            each of its equity owners is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.  For purposes of this Agreement, “Person” means an individual, a limited liability company, a partnership, a
            joint venture, a corporation, a trust, an unincorporated organization, any other entity or any government or any department or agency thereof.

        

        

        (f)         Disclosure of Information.  The Purchaser has
            had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions of the offering of the Forward Purchase Securities, as well as the terms of the Company’s proposed IPO, with the Company’s
            management.  The Purchaser has reviewed the “Summary,” “Risk Factors,” “Description of Securities,” “Management” and “Certain Relationships and Related Party Transactions” sections of the Registration Statement, dated July 11, 2019, which have
            been provided to the Purchaser.

        

        

        (g)         Restricted Securities.  The Purchaser
            understands that the Forward Purchase Securities have not been registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide
            nature of the investment intent and the accuracy of the Purchaser’s representations as expressed herein.  The Purchaser understands that the Forward Purchase Securities are “restricted securities” under applicable U.S. federal and state
            securities laws and that, pursuant to these laws, the Purchaser must hold the Forward Purchase Securities indefinitely unless they are registered with the SEC and qualified by state authorities, or an exemption from such registration and
            qualification requirements is available.  The Purchaser acknowledges that the Company has no obligation to register or qualify the Forward Purchase Securities, or any Class A Shares into which they may be converted into or exercised for, for
            resale, except pursuant to the Registration Rights.  The Purchaser further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time
            and manner of sale, the holding period for the Forward Purchase Securities, and on requirements relating to the Company which are outside of the Purchaser’s control, and which the Company is under no obligation and may not be able to satisfy. 
            The Purchaser acknowledges that the Company confidentially submitted the Registration Statement for its proposed IPO to the SEC for review.  The Purchaser understands that the offering to the Purchaser of the Forward Purchase Securities is not,
            and is not intended to be, part of the IPO, and that the Purchaser will not be able to rely on the protection of Section 11 or Section 12 of the Securities Act with respect to such Forward Purchase Securities.

        
          4

          
            

        

        (h)          No Public Market.  The Purchaser understands
            that no public market now exists for the Forward Purchase Securities, and that the Company has made no assurances that a public market will ever exist for the Forward Purchase Securities.

        

        

        (i)          High Degree of Risk.  The Purchaser understands
            that its agreement to purchase the Forward Purchase Securities involves a high degree of risk which could cause the Purchaser to lose all or part of its investment, and that it will be contractually obligated to vote its Class A Shares in favor
            of the Company’s initial Business Combination.

        

        

        (j)         Foreign Investor. The Purchaser hereby
            represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Forward Purchase Securities or any use of this Agreement, including (i) the legal
            requirements within its jurisdiction for the purchase of the Forward Purchase Securities, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the
            income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Securities. The Purchaser’s subscription and payment for and continued beneficial ownership of the Securities
            will not violate any applicable securities or other laws of the Purchaser’s jurisdiction.

        

        

        (k)        No General Solicitation.  Neither the Purchaser,
            nor any of its officers, directors, employees, agents, stockholders or partners, has either directly or indirectly, including, through a broker or finder (i) to its knowledge, engaged in any general solicitation, or (ii) published any
            advertisement in connection with the offer and sale of the Forward Purchase Securities.

        

        

        (l)          Non-Public Information.  The Purchaser
            acknowledges its obligations under applicable securities laws with respect to the treatment of material non-public information relating to the Company.

        

        

        (m)        Affiliation of Certain FINRA Members.  The
            Purchaser is neither a person associated nor affiliated with Credit Suisse Securities (USA) LLC or, to its actual knowledge, any other member of the Financial Industry Regulatory Authority (“FINRA”) that is participating in the IPO.

        
          5

          
            

        

        (n)          No Other Representations and Warranties;
              Non-Reliance.  Except for the specific representations and warranties contained in this Section 2 and in any certificate or agreement delivered pursuant hereto, none of the Purchaser nor any person acting on behalf of the Purchaser nor
            any of the Purchaser’s affiliates (the “Purchaser Parties”) has made, makes or shall be deemed to make any other express or implied representation or warranty with respect to the Purchaser and this offering, and the Purchaser Parties
            disclaim any such representation or warranty.  Except for the specific representations and warranties expressly made by the Company in Section 3 of this Agreement and in any certificate or agreement delivered pursuant hereto, the Purchaser
            Parties specifically disclaim that they are relying upon any other representations or warranties that may have been made by the Company, any person on behalf of the Company or any of the Company’s affiliates (collectively, the “Company
              Parties”).

        

        

        3.          Representations

              and Warranties of the Company.  The Company represents and warrants to the Purchaser as follows:

        

        

        (a)         Incorporation and Corporate Power.  The Company
            is an exempted company duly incorporated and validly existing and in good standing as an exempted company under the laws of the Cayman Islands and has all requisite corporate power and authority to carry on its business as presently conducted
            and as proposed to be conducted.  The Company has no subsidiaries.

        

        

        (b)          Capitalization.  The authorized share capital of
            the Company consists of:

        

        

        (i)          180,000,000 Class A Shares, none of which are issued
            and outstanding.

        

        

        (ii)          25,000,000 Class B ordinary shares of the Company,
            par value $0.00008 per share (“Class B Share(s)”), 5,562,500 of which are issued and outstanding and held by SC Health Holdings Limited (562,500 of which are subject to forfeiture to the extent that the underwriters’ over-allotment
            option in connection with the IPO is not exercised in full).  All of the issued and outstanding Class B Shares have been duly authorized, are fully paid and nonassessable and were issued in compliance with all applicable federal and state
            securities laws.

        

        

        (iii)         1,000,000 preference shares, none of which are
            issued and outstanding.

        

        

        (c)          Authorization.  All corporate action required to
            be taken by the Company’s Board of Directors and shareholders in order to authorize the Company to enter into this Agreement, and to issue the Forward Purchase Securities at the FPS Closing, and the securities issuable upon conversion or
            exercise of the Forward Purchase Securities, has been taken or will be taken prior to the FPS Closing.  All action on the part of the shareholders, directors and officers of the Company necessary for the execution and delivery of this
            Agreement, the performance of all obligations of the Company under this Agreement to be performed as of the FPS Closing, and the issuance and delivery of the Forward Purchase Securities and the securities issuable upon conversion or exercise of
            the Forward Purchase Securities has been taken or will be taken prior to the FPS Closing.  This Agreement, when executed and delivered by the Company, shall constitute the valid and legally binding obligation of the Company, enforceable against
            the Company in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’
            rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the Registration Rights may be
            limited by applicable federal or state securities laws.

        
          6

          
            

        

        (d)         Valid Issuance of Forward Purchase Securities.
            The Forward Purchase Securities, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement and the Company’s memorandum and articles of association (the “Charter”), and the
            securities issuable upon conversion or exercise of the Forward Purchase Securities, when issued in accordance with the terms of the Forward Purchase Securities and this Agreement, and registered in the register of members of the Company, will
            be validly issued, fully paid and nonassessable and free of all preemptive or similar rights, taxes, liens, encumbrances and charges with respect to the issue thereof and restrictions on transfer other than restrictions on transfer specified
            under this Agreement, applicable state and federal securities laws and liens or encumbrances created by or imposed by the Purchaser.  Assuming the accuracy of the representations of the Purchaser in this Agreement and subject to the filings
            described in Section 3(e) below, the Forward Purchase Securities will be issued in compliance with all applicable federal and state securities laws.

        

        

        (e)         Governmental Consents and Filings.  Assuming the
            accuracy of the representations and warranties made by the Purchaser in this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local
            governmental authority is required on the part of the Company in connection with the consummation of the transactions contemplated by this Agreement, except for filings pursuant to Regulation D of the Securities Act and applicable state
            securities laws.

        

        

        (f)          Compliance with Other Instruments.  The
            execution, delivery and performance of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in any violation or default (i) of any provisions of its Charter or other governing documents, (ii) of
            any instrument, judgment, order, writ or decree to which it is a party or by which it is bound, (iii) under any note, indenture or mortgage to which it is a party or by which it is bound, (iv) under any lease, agreement, contract or purchase
            order to which it is a party or by which it is bound or (v) of any provision of federal or state statute, rule or regulation applicable to the Company, in each case (other than clause (i)) which would have a material adverse effect on the
            Company or its ability to consummate the transactions contemplated by this Agreement.

        

        

        (g)          Operations.  As of the date hereof, the Company
            has not conducted, and prior to the IPO Closing the Company will not conduct, any operations other than organizational activities and activities in connection with offerings of the Forward Purchase Securities and securities in the IPO.

        
          7

          
            

        

        (h)         No General Solicitation.  Neither the Company,
            nor any of its officers, directors, employees, agents or shareholders has either directly or indirectly, including, through a broker or finder (i) engaged in any general solicitation, or (ii) published any advertisement in connection with the
            offer and sale of the Forward Purchase Securities.

        

        

        (i)          No Other Representations and Warranties;
              Non-Reliance.  Except for the specific representations and warranties contained in this Section 3 and in any certificate or agreement delivered pursuant hereto, none of the Company Parties has made, makes or shall be deemed to make any
            other express or implied representation or warranty with respect to the Company, this offering, the proposed IPO or a potential Business Combination, and the Company Parties disclaim any such representation or warranty.  Except for the specific
            representations and warranties expressly made by the Purchaser in Section 2 of this Agreement and in any certificate or agreement delivered pursuant hereto, the Company Parties specifically disclaim that they are relying upon any other
            representations or warranties that may have been made by the Purchaser Parties.

        

        

        4.          Additional

              Agreements and Acknowledgements and Waivers of the Purchaser.

        

        

        (a)         Lock-up; Transfer Restrictions. The Purchaser
            agrees that it shall not Transfer (as defined below) any Forward Purchase Securities owned by it, until the earlier of (A) one year after the Business Combination Closing and (B) the date following the Business Combination Closing on which the
            Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company’s ordinary shareholders having the right to exchange their ordinary shares of the Company for cash, securities or other
            property (the “Lock-up Period”). Notwithstanding the foregoing, if, subsequent to a Business Combination, the closing price of the Class A Shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends,
            reorganizations, recapitalizations and the like) for any twenty (20) trading days within any thirty (30) trading day period commencing at least one hundred and fifty (150) days after the Business Combination Closing, the Forward Purchase
            Securities shall be released from the lock-up referred to in this Section 4(a). Notwithstanding the first sentence hereinabove, Transfers of the Forward Purchase Securities are permitted (i) to the Company’s officers or directors, any
            affiliates or family members of any of the Company’s officers or directors, or any affiliates or direct or indirect shareholders of SC Health Holdings Limited (the “Sponsor”); (ii) in the case of an individual, as a gift to such person’s
            immediate family or to a trust, the beneficiary of which is a member of such person’s immediate family, an affiliate of such person or to a charitable organization; (iii) in the case of an individual, by virtue of laws of descent and
            distribution upon death of such person; (iv) in the case of an individual, pursuant to a qualified domestic relations order; (v) by private sales or transfers made in connection with the consummation of a Business Combination at prices no
            greater than the price at which the Forward Purchase Securities were originally purchased; (vi) by virtue of the laws of the Cayman Islands upon dissolution of the Sponsor; (vii) in the event of the Company’s liquidation, bankruptcy or
            dissolution prior to the completion of a Business Combination; (viii) in the event that, subsequent to the consummation of a Business Combination, the Company completes a liquidation, merger, share exchange or other similar transaction which
            results in all of the Company’s shareholders having the right to exchange their Class A Shares for cash, securities or other property; provided, however, that in
            the case of clauses (i) through (vi) these permitted transferees must enter into a written agreement agreeing to be bound by these transfer restrictions. As used in this Agreement, “Transfer” shall mean the (x) sale of, offer to sell, contract
            or agreement to sell, hypothecation, pledge, grant of any option to purchase or otherwise dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position or liquidation with respect to or
            decrease of a call equivalent position (within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”, and the rules and regulations of the SEC promulgated thereunder) with respect to, any of the
            Securities (excluding any pledges in the ordinary course of business for bona fide financing purposes or as part of prime brokerage arrangements), (y) entry into any swap or other arrangement that transfers to another, in whole or in part, any
            of the economic consequences of ownership of any of the Securities, whether any such transaction is to be settled by delivery of such Securities, in cash or otherwise, or (z) public announcement of any intention to effect any transaction
            specified in clause (x) or (y). For the avoidance of doubt, this Section 4(a) shall not restrict the ability to exercise any Forward Purchase Warrants in accordance with their terms.

        
          8

          
            

        

        (b)          Trust Account.

        

        

        (i)          The Purchaser hereby acknowledges that it is aware
            that the Company will establish a trust account (the “Trust Account”) for the benefit of its public shareholders upon the closing of the IPO.  The Purchaser, for itself and its affiliates, hereby agrees that it has no right, title,
            interest or claim of any kind in or to any monies held in the Trust Account, or any other asset of the Company as a result of any liquidation of the Company, except for redemption and liquidation rights, if any, the Purchaser may have in
            respect of any Class A Shares held by it.

        

        

        (ii)          The Purchaser hereby agrees that it shall have no
            right of set-off or any right, title, interest or claim of any kind (“Claim”) to, or to any monies in, the Trust Account, and hereby irrevocably waives any Claim to, or to any monies in, the Trust Account that it may have now or in the
            future, except for redemption and liquidation rights, if any, the Purchaser may have in respect of any Class A Shares held by it.  In the event the Purchaser has any Claim against the Company under this Agreement, the Purchaser shall pursue
            such Claim solely against the Company and its assets outside the Trust Account and not against the property or any monies in the Trust Account, except for redemption and liquidation rights, if any, the Purchaser may have in respect of any Class
            A Shares held by it.

        

        

        (c)          Redemption and Liquidation. The Purchaser hereby
            waives, with respect to any Forward Purchase Securities held by it, any redemption rights it may have in connection with (i) the consummation of a Business Combination, including any such rights available in the context of a shareholder vote to
            approve such Business Combination and (ii) any shareholder vote to approve an amendment to the Charter (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the Company’s Class A Shares if the Company does not
            complete its Business Combination within 18 months after the closing of the IPO or (B) with respect to any other provisions relating to the rights of the Company’s Class A Shares, it being understood that the Purchaser shall be entitled to
            redemption and liquidation rights with respect to any Class A Shares held by it.

        

        

        (d)         Voting.  The Purchaser hereby agrees that if the
            Company seeks shareholder approval of a proposed Business Combination, then in connection with such proposed Business Combination, the Purchaser shall vote any Class A Shares owned by it in favor of any proposed Business Combination.  If the
            Purchaser fails to vote any Class A Shares it is required to vote hereunder in favor of a Proposed Business Combination, the Purchaser hereby grants to the Company and any representative designated by the Company without further action by the
            Purchaser a limited irrevocable power of attorney to effect such vote on behalf of the Purchaser, which power of attorney shall be deemed to be coupled with an interest.

        
          9

          
            

        

        (e)        No Short Sales.  The Purchaser hereby agrees that
            neither it, nor any person or entity acting on its behalf or pursuant to any understanding with it, will engage in any Short Sales with respect to securities of the Company prior to the Business Combination Closing.  For purposes of this
            Section, “Short Sales” shall include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act and all types of direct and indirect stock pledges (other than pledges in the ordinary
            course of business as part of prime brokerage arrangements), forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker dealers or
            foreign regulated brokers.

        

        

        5.          Additional

              Agreement of the Company.

        

        

        (a)          NYSE Listing.  The Company will use commercially
            reasonable efforts to effect the listing of the Class A Shares and Warrants on the New York Stock Exchange (or another national securities exchange).

        

        

        (b)          Initial Business Combination. The Company
            acknowledges that the sale of the Forward Purchase Securities is a condition to the completion of the Business Combination and the Company will use reasonable best efforts to cause such sale.

        

        

        6.          FPS
              Closing Conditions.

        

        

        (a)          The obligation of the Purchaser to purchase the Forward
            Purchase Securities at the FPS Closing under this Agreement shall be subject to the fulfillment, at or prior to the FPS Closing of each of the following conditions, any of which, to the extent permitted by applicable laws, may be waived by the
            Purchaser:

        

        

        (i)          the conditions to the Business Combination Closing
            (other than the sale of the Forward Purchase Securities) shall have been satisfied;

        

        

        (ii)          the Business Combination shall be consummated
            substantially concurrently with, and immediately following, the purchase of Forward Purchase Securities;

        

        

        (iii)        the representations and warranties of the Company set
            forth in Section 3 of this Agreement of this Agreement shall have been true and correct as of the date hereof and shall be true and correct, in the case of the Company, as of the FPS Closing, as applicable, with the same effect as though such
            representations and warranties had been made on and as of such date (other than any such representation or warranty that is made by its terms as of a specified date, which shall be true and correct as of such specified date), except, in the
            case of the Company, where the failure to be so true and correct would not have a material adverse effect on the Company or its ability to consummate the transactions contemplated by this Agreement;

        
          10

          
            

        

        (iv)         the Company shall have performed, satisfied and
            complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the FPS Closing; and

        

        

        (v)          no order, writ, judgment, injunction, decree,
            determination, or award shall have been entered by or with any governmental, regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition shall be in effect,
            preventing the purchase by the Purchaser of the Forward Purchase Securities.

        

        

        (b)          The obligation of the Company to sell the Forward
            Purchase Securities at the FPS Closing under this Agreement shall be subject to the fulfillment, at or prior to the FPS Closing of each of the following conditions, any of which, to the extent permitted by applicable laws, may be waived by the
            Company:

        

        

        (i)           the Business Combination shall be consummated
            substantially concurrently with, and immediately following, the purchase of Forward Purchase Securities;

        

        

        (ii)         the representations and warranties of the Purchaser
            set forth in Section 2 of this Agreement shall have been true and correct as of the date hereof and shall be true and correct as of the FPS Closing, as applicable, with the same effect as though such representations and warranties had been made
            on and as of such date (other than any such representation or warranty that is made by its terms as of a specified date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would not
            have a material adverse effect on the Purchaser or its ability to consummate the transactions contemplated by this Agreement;

        

        

        (iii)         the Purchaser shall have performed, satisfied and
            complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the FPS Closing; and

        

        

        (iv)         no order, writ, judgment, injunction, decree,
            determination, or award shall have been entered by or with any governmental, regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition shall be in effect,
            preventing the purchase by the Purchaser of the Forward Purchase Securities.

        

        

        7.          Termination. 

            This Agreement may be terminated at any time prior to the FPS Closing:

        

        

        (a)          by mutual written consent of the Company and the
            Purchaser;

        

        

        (b)          automatically

        

        

        (i)           if the IPO is not consummated on or prior to July 1,
            2020;

        

        

        (ii)          if the Business Combination is not consummated within
            eighteen (18) months from the closing of the IPO, unless extended upon approval of the Company’s shareholders in accordance with the Charter; or

        
          11

          
            

        

        (iii)         if the Company becomes subject to any voluntary or
            involuntary petition under the United States federal bankruptcy laws or any state insolvency law, in each case which is not withdrawn within sixty (60) days after being filed, or a receiver, fiscal agent or similar officer is appointed by a
            court for business or property of the Company, in each case which is not removed, withdrawn or terminated within sixty (60) days after such appointment.

        

        

        In the event of any termination of this Agreement pursuant to this Section 7, the FPS Purchase Price (and interest thereon, if any), if previously
          paid, and all Purchaser’s funds paid in connection herewith shall be promptly returned to the Purchaser, and thereafter this Agreement shall forthwith become null and void and have no effect, without any liability on the part of the Purchaser or
          the Company and their respective directors, officers, employees, partners, managers, members, or shareholders and all rights and obligations of each party shall cease; provided, however, that nothing contained in this Section 7
          shall relieve either party from liabilities or damages arising out of any fraud or willful breach by such party of any of its representations, warranties, covenants or agreements contained in this Agreement.

        

        

        8.          General

              Provisions.

        

        

        (a)          Notices.  All notices and other communications
            given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile
            (if any) during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next Business Day, (c) five (5) Business Days after having been sent by registered or certified mail, return receipt
            requested, postage prepaid, or (d) one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next Business Day delivery, with written verification of receipt.  All communications sent to the
            Company shall be sent to: SC Health Corporation, c/o 108 Robinson Road #10-00 Singapore 068900, Attn: AJ Coloma, email: aj.coloma@sincapital.com, with a copy to the Company’s counsel at: Ropes & Gray LLP, 1211 Avenue of the Americas, New
            York, NY 10036-8704, Attn: Paul Tropp, Esq., email: paul.tropp@ropesgray.com.

        

        

        All communications to the Purchaser shall be sent to the Purchaser’s address as set forth on the signature page hereof, or to such e-mail address,
          facsimile number (if any) or address as subsequently modified by written notice given in accordance with this Section 8(a).

        

        

        (b)          No Finder’s Fees.  Each party represents that it
            neither is nor will be obligated for any finder’s fee or commission in connection with this transaction.  The Purchaser agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of
            a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Purchaser or any of its officers, employees or representatives is responsible.  The
            Company agrees to indemnify and hold harmless the Purchaser from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such
            liability or asserted liability) for which the Company or any of its officers, directors, employees or representatives is responsible.

        
          12

          
            

        

        (c)          Survival of Representations and Warranties.  All
            of the representations and warranties contained herein shall survive the FPS Closing.

        

        

        (d)         Entire Agreement.  This Agreement, together with
            any documents, instruments and writings that are delivered pursuant hereto or referenced herein, constitutes the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes all prior understandings,
            agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby.

        

        

        (e)          Successors.  All of the terms, agreements,
            covenants, representations, warranties, and conditions of this Agreement are binding upon, and inure to the benefit of and are enforceable by, the parties hereto and their respective successors.  Nothing in this Agreement, express or implied,
            is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

        

        

        (f)          Assignments.  Except as otherwise specifically
            provided herein, no party hereto may assign either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other parties.

        

        

        (g)          Counterparts.  This Agreement may be executed in
            two or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument.

        

        

        (h)          Headings.  The section headings contained in
            this Agreement are inserted for convenience only and will not affect in any way the meaning or interpretation of this Agreement.

        

        

        (i)          Governing Law.  This Agreement, the entire
            relationship of the parties hereto, and any dispute between the parties (whether grounded in contract, tort, statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the laws of the State of New
            York, without giving effect to its choice of laws principles.

        

        

        (j)          Jurisdiction.  The Parties (i) hereby
            irrevocably and unconditionally submit to the jurisdiction of the state courts of New York and to the jurisdiction of the United States District Court for the Southern District of New York for the purpose of any suit, action or other proceeding
            arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in state courts of New York or the United States District Court for the Southern
            District of New York, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named
            courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the
            subject matter hereof may not be enforced in or by such court.

        
          13

          
            

        

        (k)          Waiver of Jury Trial.  The parties hereto hereby
            waive any right to a jury trial in connection with any litigation pursuant to this Agreement and the transactions contemplated hereby.

        

        

        (l)          Amendments.  This Agreement may not be amended,
            modified or waived as to any particular provision, except with the written consent of the Company and the Purchaser.

        

        

        (m)       Severability.  The provisions of this Agreement
            will be deemed severable and the invalidity or unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof; provided that if any provision of this Agreement, as applied to any party
            hereto or to any circumstance, is adjudged by a governmental authority, arbitrator, or mediator not to be enforceable in accordance with its terms, the parties hereto agree that the governmental authority, arbitrator, or mediator making such
            determination will have the power to modify the provision in a manner consistent with its objectives such that it is enforceable, and/or to delete specific words or phrases, and in its reduced form, such provision will then be enforceable and
            will be enforced.

        

        

        (n)        Expenses.  Each of the Company and the Purchaser
            will bear its own costs and expenses incurred in connection with the preparation, execution and performance of this Agreement and the consummation of the transactions contemplated hereby, including all fees and expenses of agents,
            representatives, financial advisors, legal counsel and accountants.

        

        

        (o)          Construction.  The parties hereto have
            participated jointly in the negotiation and drafting of this Agreement.  If an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption or burden
            of proof will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement.  Any reference to any federal, state, local, or foreign law will be deemed also to refer to law as amended and all rules
            and regulations promulgated thereunder, unless the context requires otherwise.  The words “include,” “includes,” and “including” will be deemed to be followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will be
            construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context otherwise requires.  The words “this Agreement,” “herein,” “hereof,” “hereby,” “hereunder,” and
            words of similar import refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited.  The parties hereto intend that each representation, warranty, and covenant contained herein will have independent
            significance.  If any party hereto has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless
            of the relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the first representation, warranty, or covenant.

        

        

        (p)          Waiver.  No waiver by any party hereto of any
            default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not, may be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way
            any rights arising because of any prior or subsequent occurrence.

        
          14

          
            

        

        (q)         Confidentiality.  Except as may be required by
            law, regulation or applicable stock exchange listing requirements, unless and until the transactions contemplated hereby and the terms hereof are publicly announced or otherwise publicly disclosed by the Company, the parties hereto shall keep
            confidential and shall not publicly disclose the existence or terms of this Agreement.

        

        

        [Signature page follows]

        
          15

          
            

        

        

        

        IN WITNESS WHEREOF, the undersigned have executed this Agreement to be effective as of the date first set forth above.

         

        

        
          	
                  COMPANY:

                	 
	 	 	 
	
                  SC HEALTH CORPORATION

                	 
	 	 	 
	
                  By:

                	/s/ David Sin 

                	 
	 	
                  Name: David Sin 

                	 
	 	
                  Title:   Director

                  

                	 
	 	 	 
	
                  PURCHASER:

                	 
	 	 
	
                  SC HEALTH GROUP LIMITED

                	 
	 	 	 
	
                  By:

                	/s/ David Sin 	 
	
                  

                  

                	Name: David Sin 	 
	 	Title:   Director	 
	
                  

                  

                	 	 

        

        

        

        	
                Number of Forward Purchase Shares:

              	
                5,000,000

              
	
                Number of Forward Purchase Warrants:

              	
                1,250,000

              
	
                Aggregate Purchase Price for Forward Purchase Securities:

              	
                $50,000,000

              

        
          16

          
            

        

        Exhibit A

        

        

        Registration Rights

        

        

        1.          Within thirty (30) days after the Business Combination
            Closing, the Company shall use reasonable best efforts (i) to file a registration statement on Form S-3 for a secondary offering (and, with respect to clause (ii) below, within thirty (30) days following announcement of the results of the
            shareholder vote relating to the Company’s Business Combination or the results of the Company’s offer to shareholders to redeem their Class A Shares in connection with the Company’s Business Combination (whichever is later), which is referred
            to as the “Disclosure Date”) (including any successor registration statement covering the resale of the Registrable Securities a “Resale Shelf”) of (x) the Class A Shares and Warrants (and underlying Class A Shares) comprising the
            Forward Purchase Securities and the Class A Shares into which the Class B Shares are convertible, (y) any other Class A Shares and Warrants that may be acquired by the Purchaser after the date of this Agreement, including any time after the
            Business Combination Closing and (z) any other equity security of the Company issued or issuable with respect to the securities referred to in clauses (x) and (y) by way of a share capitalization or share split or in connection with a
            combination of shares, recapitalization, merger, consolidation or reorganization (collectively, the “Registrable Securities”) pursuant to Rule 415 under the Securities Act; provided, that if Form S-3 is unavailable for such a
            registration, the Company shall register the resale of the Registrable Securities on another appropriate form and undertake to register the Registrable Securities on Form S-3 as soon as such form is available, (ii) to cause the Resale Shelf to
            be declared effective under the Securities Act promptly thereafter, but in no event later than sixty (60) days after the closing of the Business Combination or the Disclosure Date, as the case may be, and (iii) to maintain the effectiveness of
            such Resale Shelf with respect to the Purchaser’s Registrable Securities until the earliest of (A) the date on which the Purchaser ceases to hold Registrable Securities covered by such Resale Shelf, (B) the date all of the Purchaser’s
            Registrable Securities covered by the Resale Shelf can be sold publicly without restriction or limitation under Rule 144 under the Securities Act and without the requirement to be in compliance with Rule 144(c)(1) under the Securities Act; and
            provided, further, with respect to Registrable Securities acquired after the Business Combination Closing, the Company shall only be obligated to amend the Resale Shelf or file a new registration statement that will constitute a
            Resale Shelf to include such Registrable Securities on two (2) occasions, each upon the written request of Purchaser with respect to at least 100,000 Registrable Securities.

        

        

        2.           In the event the Company is prohibited by applicable
            rule, regulation or interpretation by the staff (“Staff”) of the Securities and Exchange Commission (“SEC”) from registering all of the Registrable Securities on the Resale Shelf or the Staff requires that the Purchaser be
            specifically identified as an “underwriter” in order to permit such registration statement to become effective, and such Purchaser does not consent in writing to being so named as an underwriter in such registration statement, the number of
            Registrable Securities to be registered on the Resale Shelf will be reduced on a pro rata basis among all the holders of Registrable Securities to be so included, unless otherwise required by the Staff, so that the number of Registrable
            Securities to be registered is permitted by Staff and such Purchaser is not required to be named as an “underwriter”; provided, that any Registrable Securities not registered due to this paragraph 2 shall thereafter as soon as allowed
            by the SEC guidance be registered to the extent the prohibition no longer is applicable.

        

        

        3.          If at any time the Company proposes to file a
            registration statement (a “Registration Statement”) on its own behalf, or on behalf of any other Persons who have registration rights (“Other Holders”), relating to an underwritten offering of ordinary shares, or engage in an
            Underwritten Shelf Takedown (as defined below) off an existing registration statement (a “Company Offering”), then the Company will provide the Purchaser with notice in writing (an “Offer Notice”) at least five (5) Business Days
            prior to such filing, which Offer Notice will offer to include in the Registration Statement, the Purchaser’s Registrable Securities. Within five (5) Business Days (or, in the case of an Offer Notice delivered to the Purchaser in connection
            with an Underwritten Shelf Takedown, within three (3) Business Days) after receiving the Offer Notice, the Purchaser may make a written request to the Company to include some or all of Purchaser’s Registrable Securities in the Registration
            Statement. If the underwriter(s) for any Company Offering advise the Company that marketing factors require a limitation on the number of securities that may be included in the Company Offering, the number of securities to be so included shall
            be allocated as follows: (i) first, to the Company and the Other Holders, if any; and (ii) second, to the Purchaser.

        
          
            

        

        4.           At any time during which the Company has an effective
            Resale Shelf with respect to the Purchaser’s Registrable Securities, the Purchaser may make a written request (which request shall specify the intended method of disposition thereof) (a “Shelf Takedown Request”) to the Company to effect
            a sale, of all or a portion of the Purchaser’s Registrable Securities that are covered by the Resale Shelf, and the Company shall use commercially reasonable efforts to file, to the extent required by applicable law or regulation, a prospectus
            supplement (a “Shelf Takedown Prospectus Supplement”) for such purpose as soon as reasonably practicable following receipt of a Shelf Takedown Request. The Purchaser may request that any such sale be conducted as an underwritten public
            offering (an “Underwritten Shelf Takedown”). The Company shall not be obligated to effect more than two Underwritten Shelf Takedowns.

        

        

        5.          The determination of whether any offering of Registrable
            Securities pursuant to the Resale Shelf or a Shelf Takedown Prospectus Supplement will be an underwritten offering shall be made in the sole discretion of the Purchaser, after consultation with the Company, and the Purchaser shall have the
            right, after consultation with the Company, to determine the plan of distribution, including the price at which the Registrable Securities are to be sold and the underwriting commissions, discounts and fees. The Purchaser shall select the
            investment banker or bankers and managers to administer the offering, including the lead managing underwriter (provided that such investment banker or bankers and managers shall be reasonably satisfactory to the Company).

        

        

        6.           In connection with any underwritten offering, the
            Company shall enter into such customary agreements and take all such other actions in connection therewith (including those requested by the Purchaser) in order to facilitate the disposition of such Registrable Securities as are reasonably
            necessary or required, and in such connection enter into a customary underwriting agreement that provides for customary opinions, comfort letters and officer’s certificates and other customary deliverables.

        

        

        7.          The Company shall pay all fees and expenses incident to
            the performance of or compliance with its obligation to prepare, file and maintain the Resale Shelf (including the fees of its counsel and accountants). The Company shall also pay all Registration Expenses. For purposes of this paragraph 6, “Registration

              Expenses” shall mean the out-of-pocket expenses of a Company Offering or an Underwritten Shelf Takedown, including, without limitation, the following: (i) all registration and filing fees (including fees with respect to filings required
            to be made with FINRA) and any securities exchange on which the Registrable Securities are then listed; (ii) fees and expenses of compliance with securities or blue sky laws (including reasonable fees and disbursements of one counsel to the
            underwriters in connection with blue sky qualifications of the Registrable Securities); (iii) printing, messenger, telephone and delivery expenses; (iv) reasonable fees and disbursements of counsel for the Company; (v) reasonable fees and
            disbursements of all independent registered public accountants of the Company incurred specifically in connection with such Underwritten Shelf Takedown; and (vi) reasonable fees and expenses of one legal counsel selected by the Purchaser; provided, that it is understood and agreed that the Company shall be responsible for any underwriting fees, discounts, selling commissions, underwriter expenses and stock transfer taxes relating to the
            registration and sale of the Purchaser’s Registrable Securities.

        

        

        8.           The Company may suspend the use of a prospectus
            included in the Resale Shelf by furnishing to the Purchaser a written notice (“Suspension Notice”) stating that in the good faith judgment of the Company, it would be either (i) prohibited by the Company’s insider trading policy (as if
            the Purchaser were covered by such policy) or (ii) materially detrimental to the Company and its shareholders for such prospectus to be used at such time. The Company’s right to suspend the use of such prospectus under clause (ii) of the
            preceding sentence may be exercised for a period of not more than sixty (60) days after the date of such notice to the Purchaser; provided such period may be extended for an additional thirty (30) days with the consent of a majority-in-interest
            of the holders of Registrable Securities covered by the Resale Shelf; provided further, that such right to suspend the use of a prospectus shall be exercised by the Company not more than once in any twelve (12) month period. A holder of
            Registrable Securities shall not effect any sales of Registrable Securities pursuant to the Resale Shelf at any time after it has received a Suspension Notice from the Company and prior to receipt of an End of Suspension Notice (as defined
            below). The holders may recommence effecting sales of the Registrable Securities pursuant to the Resale Shelf following further written notice to such effect (an “End of Suspension Notice”) from the Company to the holders. The Company
            shall act in good faith to permit any suspension period contemplated by this paragraph to be concluded as promptly as reasonably practicable.

        

        

        9.           The Purchaser agrees that, except as required by
            applicable law, the Purchaser shall treat as confidential the receipt of any Suspension Notice (provided that in no event shall such notice contain any material nonpublic information of the Company) hereunder and shall not disclose or use the
            information contained in such Suspension Notice without the prior written consent of the Company until such time as the information contained therein is or becomes public, other than as a result of disclosure by a holder of Registrable
            Securities in breach of the terms of this Agreement.

        
          
            

        

        10.         The Company shall indemnify and hold harmless the
            Purchaser, its directors and officers, partners, members, managers, employees, agents, and representatives of such Purchaser and each person, if any, who controls the Purchaser within the meaning of the Securities Act and the Securities
            Exchange Act of 1934, as amended, and any agent thereof (collectively, “Indemnified Persons”), to the fullest extent permitted by applicable law, from and against any losses, claims, damages, liabilities, joint or several, costs
            (including reasonable costs of preparation and reasonable attorneys’ fees) and expenses, judgments, fines, penalties, interest, settlements or other amounts arising from any and all claims, demands, actions, suits or proceedings, whether civil,
            criminal, administrative or investigative, in which any Indemnified Person may be involved, or is threatened to be involved, as a party or otherwise, under the Securities Act or otherwise (collectively, “Losses”), promptly as incurred,
            arising out of, based upon or resulting from any untrue statement or alleged untrue statement of any material fact contained in the Resale Shelf (or any amendment or supplement thereto), the related prospectus, or any amendment or supplement
            thereto, or arise out of, are based upon or resulting from the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they
            were made, not misleading; provided, however, that the Company shall not be liable in any such case or to any Indemnified Person to the extent that any such Loss arises out of, is based upon or results from an untrue statement or alleged untrue
            statement or omission or alleged omission or so made in reliance upon or in conformity with information furnished by or on behalf of such Indemnified Person in writing specifically for use in the preparation of the Resale Shelf, the related
            prospectus, or any amendment or supplement thereto. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Person, and shall survive the transfer of such securities by the
            Purchaser.

        

        

        11.         The Company’s obligation under paragraph (1) of this
            Exhibit A is subject to the Purchaser’s furnishing to the Company in writing such information as the Company reasonably requests for use in connection with the Resale Shelf, the related prospectus, or any amendment or supplement thereto. The
            Purchaser shall indemnify the Company, its officers, directors, managers, employees, agents and representatives, and each person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages,
            liabilities and expenses resulting from any untrue statement or alleged untrue statement of material fact contained in the Resale Shelf, the related prospectus, or any amendment or supplement thereto or any omission or alleged omission of a
            material fact required to be stated therein or necessary to make the statements therein not misleading, but only to the extent that such untrue statement or omission is contained in any information so furnished in writing by such Purchaser
            expressly for inclusion in such document; provided that the obligation to indemnify shall be individual, not joint and several, for each Purchaser and shall be limited to the net amount of proceeds received by such Purchaser from the sale of
            Registrable Securities pursuant to the Resale Shelf.

        

        

        12.         The Company shall cooperate with the Purchaser, to the
            extent the Registrable Securities become freely tradable, to facilitate the timely preparation and delivery of certificates (not bearing any restrictive legend) representing the Registrable Securities to be offered pursuant to a Resale Shelf
            and enable such certificates to be in such denominations or amounts, as the case may be, as the Purchaser may reasonably request and registered in such names as the Purchaser may request.

        

        

        13.          If requested by the Purchaser, the Company shall as
            soon as practicable, subject to any Suspension Notice, (i) incorporate in a prospectus supplement or post-effective amendment such information as the Purchaser reasonably requests to be included therein relating to the sale and distribution of
            Registrable Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold, the purchase price being paid therefor and any other terms of the offering of the Registrable
            Securities to be sold in such offering; (ii) make all required filings of such prospectus supplement or post-effective amendment after being notified of the matters to be incorporated in such prospectus supplement or post-effective amendment;
            and (iii) supplement or make amendments to any Registration Statement if reasonably requested by the Purchaser holding any Registrable Securities.

        
          
            

        

        14.         As long as the Purchaser shall own Registrable
            Securities, the Company, at all times while it shall be reporting under the Securities Exchange Act of 1934, as amended, shall file timely (or obtain extensions in respect thereof and file within the applicable grace period) all reports
            required to be filed by the Company after the date hereof pursuant to Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and shall promptly furnish the Purchaser with true and complete copies of all such filings, unless
            filed through the SEC’s EDGAR system. The Company further covenants that it shall take such further action as the Purchaser may reasonably request, all to the extent required from time to time, to enable the Purchaser to sell the Class A Shares
            and Warrants held by the Purchaser without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 promulgated under the Securities Act, including providing any legal opinions. Upon the request of the
            Purchaser, the Company shall deliver to the Purchaser a written certification of a duly authorized officer as to whether it has complied with such requirements.

        

        

        15.          The rights, duties and obligations of the Purchaser
            under this Exhibit A may be assigned or delegated by the Purchaser in conjunction with and to the extent of any transfer or assignment of Registrable Securities by the Purchaser to any transferee or assignee.Exhibit 10.13

  

   

  

   

  

  ESCROW AGREEMENT

  

  

  ESCROW AGREEMENT, dated as of July 11, 2019 (“Agreement”), by and among SC Health Holdings Limited, a Cayman Islands exempted company (the “Sponsor”), and American Stock Transfer
    & Trust Company, LLC, a New York limited liability trust company (“Escrow Agent”) and SC Health Corporation, a Cayman Islands exempted company (the “Company”).

  

  

  WHEREAS, the Sponsor has agreed to establish an escrow account to deposit certain escrow assets, or cause an affiliate to establish an escrow account to deposit certain escrow assets, which shall
    consist of cash, with the Escrow Agent for the benefit of the holders of redeemable public warrants (the “Public Warrants”), other than the Sponsor and its affiliates (the “Beneficiaries”), issued by the Company in its initial public
    offering (the “IPO”), in an amount of $7,500,000, as such amount may be increased if the underwriters’ over-allotment option in the IPO is exercised, up to $8,625,000 if the over-allotment is exercised in full (collectively, the “Escrow
      Assets”), which Escrow Assets shall be distributed in accordance with the procedures set forth below;

  

  

  WHEREAS, this Agreement is being entered into in connection with the Company’s IPO, as described in the Company’s Registration Statement on Form S-1, File No. 333-232240 (“Registration
      Statement”), and the distribution of the Escrow Assets shall be distributed only in accordance with the terms of this Agreement; and

  

  

  WHEREAS, the Sponsor desires for the Escrow Agent to accept the Escrow Assets, in escrow, to be held and disbursed as hereinafter provided.

  

  

  IT IS AGREED:

  

  

  1.  Appointment of Escrow Agent. The Sponsor hereby appoints the Escrow Agent to act in accordance with and subject to the terms of this Agreement and the Escrow Agent hereby accepts such
    appointment and agrees to act in accordance with and subject to such terms.

  

  

  2.  Deposit of Escrow Assets. At least 24 hours prior to the effective time of the Registration Statement, the Sponsor shall deliver or cause an affiliate to deliver to the Escrow Agent
    the Escrow Assets. The Escrow Assets will be held and deposited by the Escrow Agent in an interest bearing account at J.P. Morgan Chase Bank, N.A., maintained by the Escrow Agent (the “Escrow Account”). The Escrow Assets shall only be disbursed
    in accordance with the terms and conditions of this Agreement. If at any time after the date hereof the underwriters exercise their over-allotment option in the IPO in part or in full, on the closing date for the sale of units to the underwriters upon
    such exercise, the Sponsor shall increase the Escrow Assets held by the Escrow Agent by an aggregate amount equal to an additional $0.50 for each unit exercised by the underwriters pursuant to the over-allotment option.

  
    
      

  

  
   

  

  3.  Disbursement and Reduction of the Escrow Assets.

  

  

  3.1.  The Escrow Agent shall hold the Escrow Assets during the period (the “Escrow Period”) commencing on the date hereof and ending upon the earlier of (each a “Termination Event”)
    (i) the Company’s consummation of a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving the Company and one or more businesses (a “Business Combination”), (ii) the Company’s failure
    to consummate a Business Combination within the later of (x) 18 months from the closing of the IPO and (y) such later date as may be approved by the Company’s shareholders in accordance with the Company’s amended and restated memorandum and articles of
    association (the “Charter”) or (iii) in connection with a proposed amendment to the Company’s Charter that would affect the substance or timing of the Company’s obligation to redeem 100% of its public shares if the Company does not complete a
    Business Combination within 18 months from the closing of the IPO or a proposed amendment to the terms of the Public Warrants that would affect the substance or timing of the right of the holders of the Public Warrants to receive $1.00 per Public
    Warrant in the various circumstances described in Section 7 to the Warrant Agreement, dated July 11, 2019, among American Stock Transfer & Trust Company, LLC (in this capacity, the “Warrant Agent”), the Sponsor and the Company (each
    a “Qualifying Amendment”). The Company shall promptly provide notice of a Termination Event to the Escrow Agent. Upon completion of the Escrow Period, the Escrow Agent shall promptly commence the distribution of the Escrow Assets (excluding any
    interest earned thereon) to the Beneficiaries upon receipt of, and only in accordance with, the terms of a joint letter (the “Direction Letter”) in accordance with Sections 3.2, 3.3, 3.4 or 3.5, as applicable, hereof. Notwithstanding the
    foregoing, during the Escrow Period the Escrow Agent may distribute a portion of the Escrow Assets pursuant to Section 3.5 hereof.

  

  

  3.2.  If the Termination Event is the Company’s consummation of a Business Combination, the Escrow Agent shall, as soon as practicable, distribute the Escrow Assets upon the Escrow Agent’s
    receipt of a Direction Letter substantially in the form attached hereto as Exhibit A and in accordance with the instructions thereto, to each Beneficiary who has exercised its right to require the Sponsor or its affiliate to repurchase such
    Beneficiary’s Public Warrant(s) in an amount equal to $1.00 per whole Public Warrant as directed in such Direction Letter. The balance remaining in the Escrow Account, if any, shall be returned to the Sponsor or its affiliate in accordance with the
    instruction set forth in such Direction Letter.

  

  

  3.3.  Upon written request from the Company, which may be given from time to time pursuant to an instruction letter substantially in the form attached hereto as Exhibit B, stating that a
    Qualifying Amendment has been approved, which amendment has become effective, the Escrow Agent shall, as soon as practicable, distribute from the Escrow Assets to each Beneficiary who has exercised its right to require the Sponsor or its affiliate to
    repurchase such Beneficiary’s Public Warrant(s) in an amount equal to $1.00 per whole Public Warrant as directed in such Direction Letter. The balance remaining in the Escrow Account, if any, shall remain in the Escrow Account.

  

  

  3.4.  If the Termination Event is the Company’s failure to consummate a Business Combination within the later of (x) 18 months from the closing of the IPO and (y) such later date as may be
    approved by the Company’s shareholders in accordance with the Company’s Charter, the Escrow Agent shall, as soon as practicable, distribute the Escrow Assets pro-rata to the Beneficiaries upon the Escrow Agent’s receipt of a Direction Letter
    substantially in the form attached hereto as Exhibit C, stating the Company did not consummate a Business Combination within the later of (x) 18 months from the closing of the IPO and (y) such later date as may be approved by the Company’s shareholders
    in accordance with the Charter, and the Sponsor must or cause an affiliate to distribute the Escrow Assets such that each Beneficiary receives an amount equal to $1.00 per whole Public Warrant for each Public Warrant then held by such Beneficiary. Any
    remaining Escrow Assets (or interest earned thereon) shall thereafter be distributed to the Sponsor or its affiliate as directed in Exhibit C.

  
    -2-

    
      

  

  

  

  3.5.  Upon joint written request from the Company and Sponsor, which may be given from time to time substantially in the form attached hereto as Exhibit D, the Escrow Agent shall distribute to
    the Sponsor or its affiliate as directed in Exhibit D by wire transfer the income collected on the Escrow Assets.

  

  

  3.6.  The Company and the Sponsor shall provide Credit Suisse Securities (USA) LLC (the “Representative”), the representative of the several underwriters in the IPO, with a copy of any
    Direction Letter, instruction letter or other correspondence sent to the Escrow Agent with respect to any proposed distribution or other withdrawal of all or any portion of the Escrow Assets, promptly after the issuance of same.

  

  

  4.  Concerning the Escrow Agent.

  

  

  4.1.  Good Faith Reliance. The Escrow Agent shall not be liable for any action taken or omitted by it in good faith and in the exercise of its own best judgment, and may rely conclusively
    and shall be protected in acting upon any order, notice, demand, certificate, opinion or advice of counsel (including counsel chosen by the Escrow Agent), statement, instrument, report or other paper or document (not only as to its due execution and
    the validity and effectiveness of its provisions, but also as to the truth and acceptability of any information therein contained) which is reasonably believed by the Escrow Agent to be genuine and to be signed or presented by the proper person or
    persons. The Escrow Agent shall not be bound by any notice or demand, or any waiver, modification, termination or rescission of this Agreement unless evidenced by a writing delivered to the Escrow Agent signed by the proper party or parties and, if the
    duties or rights of the Escrow Agent are affected, unless it shall have given its prior written consent thereto.

  

  

  4.2.  Indemnification. The Escrow Agent shall be indemnified and held harmless by the Sponsor from and against any reasonable and documented expenses, including reasonable outside counsel
    fees and disbursements, or loss suffered by the Escrow Agent in connection with any action, suit or other proceeding involving any claim which in any way, directly or indirectly, arises out of this Agreement, the services of the Escrow Agent hereunder,
    or the Escrow Assets held by it hereunder, other than expenses or losses arising from the gross negligence, fraud or willful misconduct of the Escrow Agent. Promptly after the receipt by the Escrow Agent of notice of any demand or claim or the
    commencement of any action, suit or proceeding, the Escrow Agent shall notify the other parties hereto in writing. In the event of the receipt of such notice, the Escrow Agent, in its sole discretion, may commence an action in the nature of
    interpleader in an appropriate court to determine ownership or disposition of the Escrow Assets or it may deposit the Escrow Assets with the clerk of any appropriate court or it may retain the Escrow Assets pending receipt of a final, non appealable
    order of a court having jurisdiction over all of the parties hereto directing to whom and under what circumstances the Escrow Assets are to be disbursed and delivered. The provisions of this Section 4.2 shall survive in the event the Escrow Agent
    resigns or is discharged pursuant to Sections 4.5 or 4.6 below.

  
    -3-

    
      

  

  

  

  4.3.  Compensation. The Escrow Agent shall be entitled to reasonable compensation from the Sponsor for all services rendered by it hereunder, as set forth in its fee proposal. The Escrow
    Agent shall also be entitled to reimbursement from the Sponsor for all reasonable and documented expenses paid or incurred by it in the administration of its duties hereunder including, but not limited to, all reasonable and documented outside counsel,
    advisors’ and agents’ fees and disbursements and all taxes or other governmental charges.

  

  

  4.4.  Further Assurances. From time to time on and after the date hereof, the Sponsor shall deliver or cause to be delivered to the Escrow Agent such further documents and instruments and
    shall do or cause to be done such further acts as the Escrow Agent shall reasonably request to carry out more effectively the provisions and purposes of this Agreement, to evidence compliance herewith or to assure itself it is protected in acting
    hereunder.

  

  

  4.5.  Resignation. The Escrow Agent may resign at any time and be discharged from its duties as escrow agent hereunder by its giving the other parties hereto written notice and such
    resignation shall become effective as hereinafter provided. Such resignation shall become effective at such time as the Escrow Agent shall turn over to a successor escrow agent appointed by the Company, the Escrow Assets held hereunder. If no new
    escrow agent is so appointed within the 60 day period following the giving of such notice of resignation, the Escrow Agent may deposit the Escrow Assets with any court it reasonably deems appropriate.

  

  

  4.6.  Discharge of Escrow Agent. The Escrow Agent shall resign and be discharged from its duties as escrow agent hereunder if so requested in writing at any time by the other parties
    hereto, jointly, provided, however, such resignation shall become effective only upon acceptance of appointment by a successor escrow agent as provided in Section 4.5.

  

  

  4.7.  Liability. Notwithstanding anything herein to the contrary, the Escrow Agent shall not be relieved from liability hereunder for its own gross negligence, fraud, or its own willful
    misconduct.

  

  

  4.8.  Waiver. The Escrow Agent hereby waives any right of set-off or any other right, title, interest or claim of any kind (“Claim”) in, or to any distribution of, the Trust
    Account (as defined in that certain Investment Management Trust Agreement, dated as of the date hereof, by and between the Company and the Escrow Agent as trustee thereunder) and hereby agrees not to seek recourse, reimbursement, payment or
    satisfaction for any Claim against the Trust Account for any reason whatsoever.

  

  

  5.  Miscellaneous.

  

  

  5.1.  Governing Law. This Agreement shall for all purposes be deemed to be made under and shall be construed in accordance with the laws of the State of New York, without giving effect to
    conflicts of law principles that would result in the application of the substantive laws of another jurisdiction.

  

  

  5.2.  Entire Agreement. This Agreement contains the entire agreement of the parties hereto with respect to the subject matter hereof and, except as expressly provided herein, may not be
    changed or modified except by an instrument in writing signed by the party to be charged.

  
    -4-

    
      

  

  

  

  5.3.  Headings. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation thereof.

  

  

  5.4.  Binding Effect. This Agreement shall be binding upon and inure to the benefit of the respective parties hereto and their legal representatives, successors and assigns.

  

  

  5.5.  Notices. Any notice or other communication required or which may be given hereunder shall be in writing and either be delivered personally, by email transmission, or be mailed,
    certified or registered mail, or by private national courier service, return receipt requested, postage prepaid, and shall be deemed given when so delivered personally or, if mailed, two business days after the date of mailing, as follows:

  

  

  If to the Company, to:

  

  

  SC Health Corporation

  108 Robinson Road #10-00

  Singapore 068900

  Attn: Angelo John Coloma

  Email: aj.coloma@sincapital.com

  

  

  with a copy to:

  

  

  Ropes & Gray LLP

  1211 Avenue of the Americas

  New York, New York 10036

  Attn: Paul Tropp

  Email: paul.tropp@ropesgray.com

  

  

  If to the Sponsor, to:

  

  

  SC Health Holdings Limited

  108 Robinson Road #10-00

  Singapore 068900

  Attn: Angelo John Coloma

  Email: aj.coloma@sincapital.com

  

  

  with a copy to:

  

  

  Ropes & Gray LLP

  1211 Avenue of the Americas

  New York, New York 10036

  Attn: Paul Tropp

  Email: paul.tropp@ropesgray.com

  
    -5-

    
      

  

  

  

  and if to the Escrow Agent, to:

  

  

  American Stock Transfer & Trust Company, LLC

  6201 15th Avenue

  Brooklyn, New York 11219

  Attn: Felix Orihuela

  Email: FOrihuela@astfinancial.com / treasurymanagement@astfinancial.com

  

  

  A copy of any notice sent hereunder shall be sent to:

  

  

  Credit Suisse Securities (USA) LLC

  Eleven Madison Avenue

  New York, New York 10010

  Attn: IBCM-Legal

  Fax No.: (212) 325-4296

  

  

  with a copy to:

  

  

  Shearman & Sterling LLP

  599 Lexington Avenue

  New York, New York 10022

  Attn: Harald Halbhuber

  Email: harald.halbhuber@shearman.com

  

  

  The parties may change the persons and addresses to which the notices or other communications are to be sent by giving written notice to any such change in the manner provided herein for giving
    notice.

  

  

  5.6.  Counterparts. This Agreement may be executed in several counterparts, each one of which shall constitute an original and may be delivered by facsimile transmission and together
    shall constitute one instrument.

  

  

  5.7.  Third-Party Beneficiary. Each of the Company and the Escrow Agent hereby acknowledges and agrees that the Representative is a third-party beneficiary of this Agreement.

  

  

  [Signature Page Follows]

  
    -6-

    
      

  

  

  

  WITNESS the execution of this Agreement as of the date first above written.

  

  

  	 	
          SPONSOR:

        
	 	 	 
	 	
          SC HEALTH HOLDINGS LIMITED

        
	 	 	 
	 	
          By:

        	/s/ David Sin  

        
	 	
          Name:

        	David Sin  

        
	 	
          Title:

        	Director 

        
	 	 	 
	 	
          ESCROW AGENT:

        
	 	 	 
	 	
          AMERICAN STOCK TRANSFER

        
	 	
          & TRUST COMPANY, LLC

        
	 	 	 
	 	
          By:

        	/s/ Michael A. Nespoli 

        
	 	
          Name:

        	Michael A. Nespoli 

        
	 	
          Title:

        	Executive Director 

        
	 	 	 
	 	
          COMPANY:

        
	 	 	 
	 	
          SC HEALTH CORPORATION

        
	 	 	 
	 	
          By:

        	/s/ David Sin  

        
	 	
          Name:

        	David Sin  

        
	 	
          Title:

        	Director 

        

  

  

  
    -7-

    
      

  

  

  

  

  

  EXHIBIT A

  

  

  [Letterhead of Company]

  [Insert date]

  

  

  American Stock Transfer & Trust Company, LLC

  6201 15th Avenue

  Brooklyn, New York 11219

  Attn: [●]

  

  

  Re: Escrow Account No. [ ] - Direction Letter

  

  

  Gentlemen:

  

  

  Pursuant to Section 3.2 of the Escrow Agreement among SC Health Holdings Limited (“Sponsor”), American Stock Transfer & Trust Company, LLC (the “Escrow Agent”) and SC Health
    Corporation, dated as of [●], 2019 (the “Escrow Agreement”), this is to advise you that the Company has consummated a Business Combination with [ ] on [ ] (the “Termination Date”) and certain holders of the Company’s Public Warrants have
    exercised their right to require the Sponsor or its affiliate to repurchase their Public Warrants. Capitalized words used herein and not otherwise defined shall have the meanings ascribed to them in the Escrow Agreement.

  

  

  Annex A contains the list of Beneficiaries who have exercised their right to require the Sponsor or its affiliate to repurchase their Public Warrants. Pursuant to Section 3.2 of the Escrow
    Agreement, you are hereby directed to distribute an aggregate of $[ ] of the Escrow Assets to each Beneficiary listed on Annex A hereto in an amount and per the instructions set forth next to the name of such Beneficiary.

  

  

  The balance remaining in the Escrow Account, if any, should be returned to the Sponsor or its affiliate at: [WIRE INSTRUCTION INFORMATION]

  

  

  Upon the distribution of all Escrow Assets pursuant to the terms hereof, the Escrow Agreement shall be terminated.

   

  

  	 	
          Very truly yours,

        
	 	 	 
	 	
          SC Health Holdings Limited

        
	 	 	 
	 	
          By:

        	 
	 	
          Name:

        	 
	 	
          Title:

        	 
	 	 	 
	 	
          SC Health Corporation

        
	 	 	 
	 	
          By:

        	 
	 	
          Name:

        	 
	 	
          Title:

        	 

  

  

  
    -8-

    
      

  

  

  

  

  

  Annex A

  

  

  [Payment Instructions]

  
    -9-

    
      

  

  

  

  

  

  EXHIBIT B

  

  

  [Letterhead of Company]

  [Insert date]

  

  

  American Stock Transfer & Trust Company, LLC

  6201 15th Avenue

  Brooklyn, New York 11219

  Attn: [●]

  

  

  Re: Escrow Account No. [ ] - Direction Letter

  

  

  Gentlemen:

  

  

  Pursuant to Section 3.3 of the Escrow Agreement among SC Health Holdings Limited (“Sponsor”), American Stock Transfer & Trust Company, LLC (the “Escrow Agent”) and SC Health
    Corporation, dated as of [●], 2019 (the “Escrow Agreement”), this is to advise you that a Qualifying Amendment has been approved, which amendment has become effective on [ ] (the “Termination Date”), and certain holders of the Company’s
    Public Warrants have exercised their right to require the Sponsor or its affiliate to repurchase their Public Warrants. Capitalized words used herein and not otherwise defined shall have the meanings ascribed to them in the Escrow Agreement.

  

  

  Annex A contains the list of Beneficiaries who have exercised their right to require the Sponsor or its affiliate to repurchase their Public Warrants. Pursuant to Section 3.3 of the Escrow
    Agreement, you are hereby directed to distribute an aggregate of $[ ] of the Escrow Assets to each Beneficiary listed on Annex A hereto in an amount and per the instructions set forth next to the name of such Beneficiary.

  

  

  The balance remaining in the Escrow Account, if any, should continue to be held by you in escrow in accordance with the terms of the Escrow Agreement.

  

  

  	 	
          Very truly yours,

        
	 	 	 
	 	
          SC Health Holdings Limited

        
	 	 	 
	 	
          By:

        	 
	 	
          Name:

        	 
	 	
          Title:

        	 
	 	 	 
	 	
          SC Health Corporation

        
	 	 	 
	 	
          By:

        	 
	 	
          Name:

        	 
	 	
          Title:

        	 

  

  

  
    -10-

    
      

  

  

  

  Annex A

  

  

  [Payment Instructions]

  
    -11-

    
      

  

  

  

  EXHIBIT C

  

  

  [Letterhead of Company]

  

  

  [Insert date]

  

  

  American Stock Transfer & Trust Company, LLC

  6201 15th Avenue

  Brooklyn, New York 11219

  Attn: [●]

  

  

  Re: Escrow Account No. [ ] - Direction Letter

  

  

  Gentlemen:

  

  

  Reference is made to the Escrow Agreement among SC Health Holdings Limited (“Sponsor”), American Stock Transfer & Trust Company, LLC (the “Escrow Agent”) and SC Health
    Corporation, dated as of [●], 2019 (the “Escrow Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Escrow Agreement. Pursuant to Section 3.4 of the Escrow Agreement, this is to
    advise you the Company did not consummate a proposed business combination within the time period set forth in the Charter, and the Sponsor or its affiliate must distribute the Escrow Assets such that each Beneficiary receives an amount equal to $1.00
    per whole Public Warrant for each whole Public Warrant then held by such Beneficiary.

  

  

  In accordance with the terms of the Escrow Agreement, you are hereby directed to distribute the Escrow Assets on [ ] to the Beneficiaries. [ ] has been selected as the “record” date for the
    purpose of determining the Beneficiaries entitled to receive $1.00 per whole Public Warrant held by such Beneficiary as of such date, as determined by you in your capacity as the Warrant Agent. You agree to be the paying agent of record and in your
    separate capacity as paying agent to distribute said funds directly to the Beneficiaries in accordance with the terms of the Escrow Agreement.

  

  

  Any remaining amounts in the Escrow Account following payments to the Beneficiaries shall be distributed to the Sponsor or its affiliate at: [WIRE INSTRUCTION INFORMATION]

  

  

  Upon the distribution of all of the funds comprising the Escrow Assets, your obligations under the Escrow Agreement shall be terminated.

  
    -12-

    
      

  

  

  

  	 	
          Very truly yours,

        
	 	 	 
	 	 	 
	 	
          SC Health Holdings Limited

        
	 	 	 
	 	
          By:

        	 
	 	
          Name:

        	 
	 	
          Title:

        	 
	 	 	 
	 	
          SC Health Corporation

        
	 	 	 
	 	
          By:

        	 
	 	
          Name:

        	 
	 	
          Title:

        	 

  

  

  
    -13-

    
      

  

  EXHIBIT D

  

  

  [Letterhead of Company]

  [Insert date]

  

  

  American Stock Transfer & Trust Company, LLC

  6201 15th Avenue

  Brooklyn, New York 11219

  Attn: [●]

  

  

  Re: Escrow Account No. [ ] - Direction Letter

  

  

  Gentlemen:

  

  

  Pursuant to Section 3.5 of the Escrow Agreement among SC Health Holdings Limited (“Sponsor”), American Stock Transfer & Trust Company, LLC (the “Escrow Agent”) and SC Health
    Corporation, dated as of [●], 2019 (the “Escrow Agreement”), the Sponsor hereby requests you to deliver to it or its affiliate $      of the interest income earned on the Escrow Assets as of the date hereof.

  

  

  In accordance with the terms of the Escrow Agreement, you are hereby directed and authorized to transfer (via wire transfer) such funds promptly upon your receipt of this letter to the Sponsor’s
    or its affiliate’s account at:

  

  

  [WIRE INSTRUCTION INFORMATION]

  

  

  	 	
          Very truly yours,

        
	 	 	 
	 	
          SC Health Holdings Limited

        
	 	 	 
	 	
          By:

        	 
	 	
          Name:

        	 
	 	
          Title:

        	 
	 	 	 
	 	
          SC Health Corporation

        
	 	 	 
	 	
          By:

        	 
	 	
          Name:

        	 
	 	
          Title:

        	 

  

  

  

  

  -14-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]